AgeX Therapeutics Inc

AgeX Therapeutics Inc (ticker: SER) is a small‑cap biotechnology company focused on regenerative medicine and longevity therapies. The business works with pluripotent stem‑cell platforms and related technologies to explore treatments for age‑related conditions and tissue regeneration. As a development‑stage company with a market capitalisation near $52 million, it has limited or no commercial revenues and depends on research progress, clinical milestones, partnerships and financing. Share price moves can be driven by trial results, licensing agreements or funding events, while failed studies, regulatory setbacks or cash shortages can lead to sharp declines. Investors typically evaluate intellectual property, management experience and cash runway when assessing prospects. Given the long timelines, scientific uncertainty and binary outcomes common in biotech, the stock can be highly volatile. This is general educational information, not personal investment advice; suitability depends on an investor’s risk tolerance and time horizon. Values can rise and fall and returns are not guaranteed.